Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

6.71USD
19 Aug 2019
Change (% chg)

-- (--)
Prev Close
$6.71
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,670,153
52-wk High
$25.96
52-wk Low
$6.07

Select another date:

Thu, Aug 15 2019

Teva settles multibillion-dollar drug kickback case ahead of trial

Teva Pharmaceutical Industries Ltd has agreed on the eve of trial to settle a multibillion-dollar whistleblower lawsuit alleging it paid doctors kickbacks to prescribe its Parkinson's disease drug Azilect and multiple sclerosis treatment Copaxone.

Judge certifies Niaspan 'pay-for-delay' class action against AbbVie, Teva

A federal judge on Wednesday certified a class of drug purchasers suing AbbVie Inc and Teva Pharmaceutical Industries Ltd over an alleged anticompetitive agreement that delayed the release of a generic version of the cholesterol drug Niaspan.

U.S. lawmakers push Mylan, Teva over drug pricing probe

WASHINGTON The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

UPDATE 3-U.S. lawmakers push Mylan, Teva over drug pricing probe

WASHINGTON, Aug 14 The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

U.S. lawmakers push Mylan, Teva over drug pricing probe -statement

WASHINGTON, Aug 14 The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Israel's Teva Pharm profit falls less than expected, CFO to leave

TEL AVIV Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter profit on Wednesday and said its chief financial officer was leaving the company.

UPDATE 2-Israel's Teva Pharm profit falls less than expected, CFO to leave

* Migraine drug Ajovy Q2 sales reach $23 mln (Adds CEO comments from conference call, interview)

Israel's Teva Pharm Q2 profit falls less than expected

TEL AVIV, Aug 7 Israel-based Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter profit on Wednesday and reaffirmed its full year outlook.

Teva settles California's Provigil pay-for-delay claims for $69 million

California's attorney general on Monday said Teva Pharmaceutical Industries Ltd had reached a $69 million settlement resolving claims it engaged in an anticompetitive scheme that delayed the release of cheaper generic versions of the wakefulness drug Provigil.

Teva loses challenge to Bausch patent on drug Relistor

Canadian pharmaceutical company Bausch Health Companies Inc (formerly Valeant Pharmaceuticals) on Wednesday won a ruling protecting its drug Relistor from U.S. generic competition from Teva Pharmaceuticals Industries Ltd.

Select another date: